- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-PAI1/ SERPINE1/ PAI monoclonal antibody
Anti-PAI1/ SERPINE1/ PAI antibody for FACS & in-vivo assay
Go to SERPINE1/SERPINE1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T15556-Ab-1/ GM-Tg-hg-T15556-Ab-2 | Anti-Human SERPINE1 monoclonal antibody | Human |
| GM-Tg-rg-T15556-Ab-1/ GM-Tg-rg-T15556-Ab-2 | Anti-Rat SERPINE1 monoclonal antibody | Rat |
| GM-Tg-mg-T15556-Ab-1/ GM-Tg-mg-T15556-Ab-2 | Anti-Mouse SERPINE1 monoclonal antibody | Mouse |
| GM-Tg-cynog-T15556-Ab-1/ GM-Tg-cynog-T15556-Ab-2 | Anti-Cynomolgus/ Rhesus macaque SERPINE1 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T15556-Ab-1/ GM-Tg-felg-T15556-Ab-2 | Anti-Feline SERPINE1 monoclonal antibody | Feline |
| GM-Tg-cang-T15556-Ab-1/ GM-Tg-cang-T15556-Ab-2 | Anti-Canine SERPINE1 monoclonal antibody | Canine |
| GM-Tg-bovg-T15556-Ab-1/ GM-Tg-bovg-T15556-Ab-2 | Anti-Bovine SERPINE1 monoclonal antibody | Bovine |
| GM-Tg-equg-T15556-Ab-1/ GM-Tg-equg-T15556-Ab-2 | Anti-Equine SERPINE1 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T15556-Ab-1/ GM-Tg-hg-T15556-Ab-2; GM-Tg-rg-T15556-Ab-1/ GM-Tg-rg-T15556-Ab-2; GM-Tg-mg-T15556-Ab-1/ GM-Tg-mg-T15556-Ab-2; GM-Tg-cynog-T15556-Ab-1/ GM-Tg-cynog-T15556-Ab-2; GM-Tg-felg-T15556-Ab-1/ GM-Tg-felg-T15556-Ab-2; GM-Tg-cang-T15556-Ab-1/ GM-Tg-cang-T15556-Ab-2; GM-Tg-bovg-T15556-Ab-1/ GM-Tg-bovg-T15556-Ab-2; GM-Tg-equg-T15556-Ab-1/ GM-Tg-equg-T15556-Ab-2 |
| Products Name | Anti-SERPINE1 monoclonal antibody |
| Format | mab |
| Target Name | SERPINE1 |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-SERPINE1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation | Lyophilized from sterile PBS, PH 7.4 |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | Products Developing | Multi-species PAI1/ SERPINE1/ PAI VLP (virus-like particle) (Products Developing) |
| Cytokine | GM-Tg-g-T15556-Ag-1 | serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 (SERPINE1) protein |
| ORF Viral Vector | vGMAP000049 | Human SERPINE1 Adenovirus particle |
| ORF Viral Vector | pGMAP000049 | Human SERPINE1 Adenovirus plasmid |
| ORF Viral Vector | vGMLP000493 | human SERPINE1 Lentivirus particle |
| ORF Viral Vector | pGMLP000493 | human SERPINE1 Lentivirus plasmid |
| ORF Viral Vector | pGMLPm002084 | mouse Serpine1 Lentivirus plasmid |
| ORF Viral Vector | vGMLPm002084 | mouse Serpine1 Lentivirus particle |
Target information
| Target ID | GM-T15556 |
| Target Name | SERPINE1 |
| Gene ID | 5054,18787,24617,713883,403476,100127105,281375,100033931 |
| Gene Symbol and Synonyms | PAI,PAI-1,PAI1,PAI1A,Pai1aa,Planh,PLANH1,RATPAI1A,SERPINE1 |
| Uniprot Accession | P05121,P20961,P13909 |
| Uniprot Entry Name | PAI1_HUMAN,PAI1_RAT,PAI1_BOVIN |
| Protein Sub-location | Transmembrane Protein |
| Category | Therapeutics Target, Cytokine Target |
| Disease | Ovary Cancer, Malignant neoplasm of bladder |
| Gene Ensembl | ENSG00000106366 |
| Target Classification | N/A |
The target: SERPINE1, gene name: SERPINE1, also named as PAI, PAI-1, PAI1, PLANH1. This gene encodes a member of the serine proteinase inhibitor (serpin) superfamily. This member is the principal inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA), and hence is an inhibitor of fibrinolysis. The protein also functions as a component of innate antiviral immunity. Defects in this gene are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency), and high concentrations of the gene product are associated with thrombophilia. [provided by RefSeq, Aug 2020].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
